AAOS: Best TKA Outcome at Very-High Volume Hospitals

Share this content:
AAOS: Best TKA Outcome at Very-High Volume Hospitals
AAOS: Best TKA Outcome at Very-High Volume Hospitals

MONDAY, March 7, 2016 (HealthDay News) -- Undergoing total knee arthroplasty (TKA) at very-high volume hospitals is associated with the lowest lifetime costs and greatest benefits, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 1 to 5 in Orlando, Fla.

Jayme C. Burket, Ph.D., from the Hospital for Special Surgery in New York City, and colleagues compared the cost-effectiveness of primary elective unilateral TKA over a patient's lifetime among low, medium, high, and very-high volume hospitals using data from the New York Statewide Planning and Research Cooperative System from 1997 to 2014 for young (89,796 cases) and Medicare-age (111,492 cases) cohorts.

The researchers found that the lowest lifetime costs and greatest benefits were seen for TKA surgery performed at very-high volume hospitals in the young cohort (costs: $45,684; $43,222; $41,244; and $29,899, for low, medium, high, and very-high volume hospitals, respectively; corresponding benefits: 17.07, 17.15, 17.19, and 17.22, quality-adjusted life-years). Similar results were seen in the Medicare cohort, although the cost savings were more modest. Total societal cost savings would be approximately $23 million annually if patients from low, medium, and high volume hospitals in New York State regionalized to very-high volume hospitals.

"We found that knee replacement surgery at higher-volume hospitals is less costly over a patient's lifetime and provides better outcomes," Burket said in a statement.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »